Mannitol

Chemical formula: C₆H₁₄O₆ Molecular mass: 182.172 g/mol PubChem compound: 6251

Therapeutic indications

Mannitol is indicated for:

Oliguric phase of acute renal failure

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Promotion of diuresis in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible oliguric renal failure becomes established.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

50-200 g/day

Raised intracranial pressure, cerebral oedema

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Reduction of intracranial pressure and cerebral oedema, when the blood-barrier is intact.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

1.5-2.0 g/kg

Elevated intraocular pressure

Population group: only children (1 year - 12 years old) , adolescents (12 years - 18 years old) , adults (18 years old or older)

Reduction of elevated intraocular pressure when it cannot be lowered by other means.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

1.5-2.0 g/kg

Elimination of renally excreted toxic substances in poisoning

Population group: only adolescents (12 years - 18 years old) , adults (18 years old or older)

Promotion of elimination of renally excreted toxic substances in poisoning.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

25 g

Oliguric phase of acute renal failure

Population group: only children (1 year - 12 years old)

Promotion of diuresis in the prevention and/or treatment of the oliguric phase of acute renal failure before irreversible oliguric renal failure becomes established.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

0.5-1.5 g/kg

Cystic fibrosis (CF)

Population group: only adults (18 - 65 years old)

Mannitol is indicated for the treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

800 mg in 2 divided doses daily

Contraindications

Mannitol is contraindicated in the following cases:

Hypersensitivity to mannitol

Mannitol allergy

Severe dehydration

Severe dehydration

Hyperosmolarity

Hyperosmolarity

Anuria

Anuria

Severe heart failure

Heart failure

Severe pulmonary congestion, pulmonary oedema

at least one of

Pulmonary congestion
Pulmonary edema

Intracranial bleeding

Intracranial hemorrhage

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈